**List of Progress in Hematology "Review Series" 2015-2016
\*\*\*2016\*\*\*
Management and analyses of registry database of hematopoietic stem cell transplantation in Japan (Edited by Yoshinobu Kanda)**

1. Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int. J. Hematol. 103: 3-10, 2016
2. Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int. J. Hematol. 103: 11-9, 2016
3. Kuwatsuka Y. Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries. Int. J. Hematol. 103: 20-4, 2016

**Mesenchymal Stromal/Stem Cells (Edited by Yasuo Miura)**

1. Miura Y. Human bone marrow mesenchymal stromal/stem cells: current clinical applications and potential for hematology. Int. J. Hematol. 103: 122-8, 2016
2. Kim N, Cho S-G. Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. Int. J. Hematol. 103: 129-37, 2016
3. Mabuchi Y, Matsuzaki Y, Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs. Int. J. Hematol. 103: 138-44, 2016
4. Nguyen TM, Arthur A, Gronthos S. The role of Eph/ephrin molecules in stromal–hematopoietic interactions. Int. J. Hematol. 103: 145-54, 2016

**Pediatric MDS/MPN (Edited by Atsushi Manabe)**

1. Hasegawa D. The current perspective of low-grade myelodysplastic syndrome in children. Int. J. Hematol. 103: 360-4, 2016
2. Sashida S. Evolution of myeloid leukemia in children with Down syndrome. Int. J. Hematol. 103: 365-72, 2016
3. Dalle J-H, de Latour RP. Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Int. J. Hematol. 103: 373-9, 2016
4. Kook H, Chung N-G, Kang HJ, Im HJ. Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology. Int. J. Hematol. 103: 380-6, 2016

**Regulation of hematopoietic stem cells (Edited by Hideo Ema)**

1. Hao S, Chen C, Cheng T. Cell cycle regulation of hematopoietic stem or progenitor cells. Int. J. Hematol. 103: 487-97, 2016
2. Wang Z, Ema H. Mechanisms of self-renewal in hematopoietic stem cells. Int. J. Hematol. 103: 498-509, 2016
3. Xiaomin W, Yajing C, Weili W, Weiping Y. mTORC signaling in hematopoiesis. Int. J. Hematol. 103: 510–518, 2016
4. Yu Z, Yingdai G. Novel chemical attempts at ex vivo hematopoietic stem cell expansion. Int. J. Hematol. 103: 519-529, 2016

 **Epigenetic and metabolic regulation in hematopoiesis/leukemogenesis (Edited by Atsushi Hirao)**

1. Jiang Y, Nakada D. Cell intrinsic and extrinsic regulation of leukemia cell metabolism. Int. J. Hematol. 103: 607-616, 2016
2. Celik H, Kramer A, Challen GA, DNA methylation in normal and malignant hematopoiesis. Int. J. Hematol. 103: 617-626, 2016
3. Inoue S, Lemonnier F, Mak TW. Roles of IDH1/2 and TET2 mutations in myeloid disordersInt. J. Hematol. 103: 627-633, 2016
4. Takamatsu-Ichihara E, Kitabayashi I. The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies. Int. J. Hematol. 103: 634-642, 2016

**Current Gene therapy for hematological disorders (Edited by Masato Yamamoto and Kenzaburo Tani)**

1. Yamamoto M, Tani K. Current status and recent advances of gene therapy in hematological diseases. Int. J. Hematol. 104: 4-5, 2016
2. Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int. J. Hematol. 104: 6-17, 2016
3. Osborn MJ, Belanto JJ, Tolar J, Voytas DF. Gene editing and its application for hematological diseases. Int. J. Hematol. 104: 18-28, 2016
4. Domingo-Musibay E, Yamamoto M. Gene and virotherapy for hematological malignancies. Int. J. Hematol. 104: 29-41, 2016
5. Tani K. Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world. Int. J. Hematol. 104: 42-72, 2016

**Recent advance in the diagnosis and treatment of bone marrow failure syndromes (Edited by Shinji Nakao)**

1. Nakao S. Diagnostic problems in acquired bone marrow failure syndromes. Int. J. Hematol. 104: 151-152, 2016
2. Narita A, Kojima S. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. Int. J. Hematol. 104: 153-158, 2016
3. Marsh JCW, Mufti GJ. Clinical significance of acquired somatic mutations in aplastic anaemia. Int. J. Hematol. 104: 159-167, 2016
4. Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. Int. J. Hematol. 104: 168-174, 2016

**Mechanisms of action of novel drugs in multiple myeloma and those responsible for the acquired resistance (Edited by Shinsuke Iida)**

1. Iida S. Mechanisms of action and resistance for multiple myeloma novel drug treatments. Int. J. Hematol. 104: 271-272, 2016
2. Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int. J. Hematol. 104: 273-280, 2016
3. Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. Int. J. Hematol. 104: 281-292, 2016
4. Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Int. J. Hematol. 104: 293-299, 2016
5. Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int. J. Hematol. 104: 300-309, 2016

**\*\*\*2015\*\*\***

**Molecular pathogenesis and treatment strategies ofadult leukemia (Edited by Kazunori Ohnishi)**

1. Patel B, Hirsch C, Clemente M, Sekeres M, Makishima H, Maciejewski JP. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms. Int. J. Hematol. 101: 213-8, 2015
2. Rodríguez D, Bretones G, Arango JR, Valdespino V, Campo E, Quesada V, López-Otín C. Molecular pathogenesis of CLL and its evolution. Int. J. Hematol. 101: 219-28, 2015
3. Zoi K, Cross NCP. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int. J. Hematol. 101:229-42, 2015
4. Yanada M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. Int. J. Hematol. 101:243-54, 2015

**Transcriptional control in myeloid cell development and related diseases (Edited by Tomohiko Tamura)**

1. Imperato MR. Cauchy P, Obier N, Bonifer C. The RUNX1–PU.1 axis in the control of hematopoiesis. Int. J. Hematol. 101: 319-29, 2015
2. Friedman AD. C/EBPa in normal and malignant myelopoiesis. Int. J. Hematol. 101: 330-41, 2015
3. Tamura T, Kurotaki D, Koizumi S. Regulation of myelopoiesis by the transcription factor IRF8. Int. J. Hematol. 101:342-51, 2015
4. Yokoyama A. Molecular mechanisms of MLL-associated leukemia. Int. J. Hematol. 101:352-61, 2015

 **The latest development in GVHD management (Edited by Makoto Murata)**

1. Shono, Y, Docampo MD, Peled JU, Perobelli SM, Jenq RR. Intestinal microbiota-related effects on graft-versus-host disease. Int. J. Hematol. 101: 428-37, 2015
2. Nakasone H, Sahaf B, Miklos DB. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. Int. J. Hematol. 101:438-51, 2015
3. Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment. Int. J. Hematol. 101:452-66, 2015
4. Murata M. Prophylactic and therapeutic treatment of graft-versus-host disease

in Japan. Int. J. Hematol. 101:467-86, 2015

**Preleukemia/prelymphoma (Edited by Shigeru Chiba)**

1. Shlush LI, Zandi S, Itzkovitz S, Schuh AC. Aging, clonal hematopoiesis and preleukemia: not just bad luck? Int. J. Hematol. 102:513-22, 2015
2. Sakata-Yanagimoto M. Multistep tumorigenesis in peripheral T cell lymphoma. Int. J. Hematol. 102:523-27, 2015
3. Kikushige Y, Miyamoto T. Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia. Int. J. Hematol. 102:528-35, 2015